Dr. Agarwal’s Healthcare Limited, a leading eye care provider in India, has launched its Initial Public Offering (IPO), attracting strong interest from investors. The IPO, open from January 29 to January 31, 2025, is expected to list on BSE and NSE on February 5, 2025. This article delves into the Dr. Agarwal’s IPO Grey Market Premium (GMP) trends, potential returns, and key investment details.
Dr. Agarwal’s Healthcare IPO Details
- IPO Size: ₹3,027.26 Crore (Fresh Issue: ₹300 Cr, Offer for Sale: ₹2,727.26 Cr)
- Price Band: ₹382-₹402 per share
- Lot Size: 35 shares
- Retail Quota: 35%, QIB: 50%, NII: 15%
- Minimum Investment: ₹14,070
- Lead Managers: Kotak Mahindra, Morgan Stanley, Jefferies, Motilal Oswal
- Company Overview: Operating 193 facilities with 737 doctors, the company served 2.13 million patients as of September 30, 2024.
Dr. Agarwal’s IPO GMP (Grey Market Premium) Trend
The GMP represents the price at which shares are traded unofficially before listing. A higher GMP signals strong demand, while a decline may indicate lukewarm interest.
Day-wise GMP Movement
| Date | IPO Price | GMP | Sub2 Sauda Rate | Estimated Listing Price | Last Updated |
|---|---|---|---|---|---|
| 29-01-2025 | ₹402.00 | ₹12 | 300/4500 | ₹414 (2.99%) | 10:07 AM |
| 28-01-2025 | ₹402.00 | ₹12 | 300/4500 | ₹414 (2.99%) | 11:29 PM |
| 27-01-2025 | ₹402.00 | ₹13 | 300/4500 | ₹415 (3.23%) | 11:00 PM |
| 26-01-2025 | ₹402.00 | ₹32 | 900/13500 | ₹434 (7.96%) | 11:28 PM |
| 25-01-2025 | ₹402.00 | ₹30 | 800/12000 | ₹432 (7.46%) | 11:35 PM |
| 24-01-2025 | ₹402.00 | ₹54 | 1400/21000 | ₹456 (13.43%) | 11:32 PM |
Check>> Latest IPO Grey Market Premium
Official registrar for Dr. Agarwal’s Healthcare IPO :
Kfin Technologies, a leading financial services provider, has been appointed as the official registrar for Dr. Agarwal’s Healthcare IPO. As the registrar, Kfin Technologies will manage the share allotment process, handle investor queries, and ensure smooth post-IPO services, including refunds and crediting shares to Demat accounts. Their expertise in handling large public offerings ensures a seamless experience for investors participating in the IPO.
Is Dr. Agarwal’s Healthcare IPO a Good Investment?
Reasons to Invest:
✔ Strong Market Position: Dr. Agarwal’s is a reputed healthcare brand with an extensive network across India.
✔ Growth Potential: The company is expanding its footprint, boosting long-term revenue prospects.
✔ Stable Financials: Revenue of ₹837.94 Cr (Sep 2024) and Profit After Tax (PAT) of ₹39.56 Cr showcase financial stability.
✔ Anchor Investors: The IPO secured ₹875.51 Cr from prominent investors, indicating market confidence.
Risks to Consider:
⚠ GMP Volatility: The GMP has seen fluctuations, from ₹54 on Jan 24 to ₹12 on Jan 29, suggesting changing investor sentiment.
⚠ Healthcare Sector Challenges: Regulatory hurdles and competition in the healthcare industry may impact long-term performance.
⚠ Offer for Sale (OFS) Component: A large portion (₹2,727.26 Cr) is an OFS, meaning existing stakeholders are selling, which may indicate reduced internal confidence.
Stay updated with WatchIPO GMP for latest Dr. Agarwal’s IPO GMP trends for a well-informed investment strategy!